Effect of antispasmodic agents, alone or in combination, in the treatment of Irritable Bowel Syndrome: Systematic review and meta-analysis

Revista de Gastroenterologia de Mexico

Volumn 77, Issue 2, 2012, Pages 82-90

  Martinez Vazquez M A ^a   Vazquez Elizondo G ^a   Gonzalez Gonzalez J A ^a   Gutierrez Udave R ^a   Maldonado Garza, H J ^a   Bosques Padilla, F J ^a  

^a HOSPITAL UNIVERSITARIO DR JOSÉ ELEUTERIO GONZÁLEZ   (Mexico)

Author keywords

Abdominal Distension; Abdominal Pain; Alverine Simethicone; Antispasmodics; Global Improvement; Irritable Bowel Syndrome; Mexico; Otilonium; Pinaverium Simethicone

Indexed keywords

CHOLINERGIC RECEPTOR BLOCKING AGENT;

COMBINATION DRUG THERAPY; HUMAN; IRRITABLE BOWEL SYNDROME; META ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC);

DRUG THERAPY, COMBINATION; HUMANS; IRRITABLE BOWEL SYNDROME; PARASYMPATHOLYTICS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84863602593     PISSN: 03750906     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rgmx.2012.04.002     Document Type: Short Survey

References (49)

1. Schmulson M, Vargas JA, López-Colombo A, et al. Prevalence and clinical characteristics of the IBS subtypes according to the Rome III criteria in patients from a clinical, multicentric trial. A report from the Mexican IBS Working Group. Rev Gastroenterol Mex. 2010;75:427-38.
2. Drossman DA, Morris CB, Hu Y et al. A prospective assessment of bowel habit in irritable bowel syndrome in women: defining an alternator. Gastroenterology. 2005;128:580-9. (Pubitemid 40585359)
3. Thompson WG, Longstreth GF, Drossman DA, et al. Functional bowel disorders and functional abdominal pain. Gut. 1999;45:43-7.
4. Camilleri M, Prather CM. The irritable bowel syndrome: mechanisms and a practical approach to management. Ann Intern Med. 1992;116:1001-8.
5. Kellow JE, Azpiroz F, Delvaux M, et al. Applied principles of neurogastroenterology: physiology/motility sensation. Gastroenterology. 2006;130:1412-20.
6. Drossman DA, Camilleri M, Mayer EA, et al. AGA technical review on irritable bowel syndrome. Gastroenterology. 2002;123:2108-31. (Pubitemid 35408332)
7. Lesbros-Pantoflickova D, Michetti P, Fried M, et al. Metaanalysis: the treatment of irritable bowel syndrome. Aliment Pharmacol Ther. 2004;20:1253-69. (Pubitemid 40040072)
8. Poynard T, Naveau S, Mory B, et al. Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther. 1994;8:499-510. (Pubitemid 24324487)
9. Brandt LJ, Bjorkman D, Fennerty B, et al. Systematic review on the management of irritable bowel syndrome in North America. Am J Gastroenterol. 2002;97 Suppl. 11:S7-26.
10. Tack J, Fried M, Houghton LA. Systematic review: the efficacy of treatments for irritable bowel syndrome - a European perspective. Aliment Pharmacol Ther. 2006;24:183-205. (Pubitemid 43972890)
11. Sacks HS, Berrier J, Reitman D, et al. Meta-analyses of randomized controlled trials. N Engl J Med. 1987;316:450-5. (Pubitemid 17035572)
12. Jadad AR, McQuay HJ. A high-yield strategy to identify randomized controlled trials for systematic reviews. Online J Curr Clin Trials. 1993:33.
13. Moher D, Jadad AR, Nichol G, et al. Assessing the quality of randomized controlled trials: an annotated bibliography of scales and checklists. Control Clin Trials. 1995;16:62-73.
14. Moher D, Jadad AR, Tugwell P. Assessing the quality of randomized controlled trials. Current issues and future directions. Int J Technol Assess Health Care. 1996;12:195-208. (Pubitemid 26195520)
15. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in metaanalyses. Br Med J. 2003;327:557-60.
16. Demets DL. Methods for combining randomized clinical trials: strengths and limitations. Stat Med. 1987;6:341-50.
17. Egger M, Davey Smith G, Schneider M, et al. Bias in metaanalysis detected by a simple, graphical test. Br Med J. 1997;315:629-34. (Pubitemid 27387172)
18. McQuay HJ, Moore RA. Using numerical results from systematic reviews in clinical practice. Ann Intern Med. 1997;126:712-20. (Pubitemid 27184043)
19. Ford AC, Talley NJ, Spiegel BM, et al. Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and metaanalysis. Br Med J. 2008;337:313.
20. Clave P, Acalovschi M, Triantafillidis JK, et al. Randomised clinical trial: otilonium bromide improves frequency of abdominal pain, severity of distention and time to relapse in patients with irritable bowel syndrome. Aliment Pharmacol Ther. 2011;34:432-42.
21. Wittmann T Paradowski L, Ducrotte P, et al. Clinical trial: the efficacy of alverine citrate/simethicone combination on abdominal pain/discomfort in irritable bowel syndrome - a randomized, double-blind, placebo-controlled study. Aliment Pharmacol Ther. 2010;31:615-24.
22. Glass GV. Primary, Secondary, and Meta-Analysis of Research. Educational Researcher. 1976;5:3-8.
23. Remes-Troche JM, Tamayo JL, Vargas JA, et al. Pinaverium bromide bromide plus simethicone is effective on abdominal pain, in a 12-week randomized placebo-controlled trial in IBS. A report from the Mexican IBS-Working Group. Gastroenterology. 2011;140 Suppl. 1:M1332.
24. Schmulson MJ, Soto-Perez JC, Vargas JA, et al. Can pinaverium bromide bromide plus simethicone improve bloating and objective abdominal distention during a 12-week randomized-clinical trial in IBS? A report from the Mexican IBSWorking Group. Gastroenterology. 2011;140 Suppl. 1:M1327.
25. Ford AC, Brandt LJ, Young C, et al. Efficacy of 5-HT3 antagonists and 5-HT4 agonists in irritable bowel syndrome: systematic review and meta-analysis. Am J Gastroenterol. 2009;104:1831-43.
26. Smeeth L, Haines A, Ebrahim S. Numbers needed to treat derived from meta-analyses-sometimes informative, usually misleading. BMJ. 1999;318:1548-51. (Pubitemid 29255803)
27. Levy C, Charbonnier A, Cachin M. Pinaverium bromide bromide and functional colonic disease (double-blind study. Sem Hop Ther. 1977;53:372-4. (Pubitemid 8181043)
28. Delmont J. The value of adding an antispasmodic musculotropic agent in the treatment of painful constipation in functional colopathies with bran. Double-blind study. Med Chir Dig. 1981;10:365-70. (Pubitemid 11089359)
29. Connell AM. Physiological and clinical assessment of the effect of the musculotropic agent mebeverine on the human colon. Br Med J. 1965;2:848-51.
30. Tasman-Jones C. Mebeverine in patients with the irritable colon syndrome: double blind study. N Z Med J. 1973;77:232-5.
31. Berthelot JCM. Etude controleÂe en double aveugle DUSPATALIN (Mebeverine) contre placebo, dans le traitement du colon irritable. Gaz Med France. 1981;88:2341-443.
32. Kruis W, Weinzierl M, Schussler P, et al. Comparison of the therapeutic effect of wheat bran, mebeverine and placebo in patients with the irritable bowel syndrome. Digestion. 1986;34:196-201. (Pubitemid 16064246)
33. Secco GB, Di Somma C, Arnulfo G, et al. Controlled clinical study of the action of mebeverine hydrochloride in the treatment of irritable colon. Minerva Med. 1983;74:699-702. (Pubitemid 13117565)
34. Enck P, Klosterhalfen S, Kruis W. Determination of placebo effect in irritable bowel syndrome. Dtsch Med Wochenschr. 2005;130:1934-7. (Pubitemid 41232895)
35. Barbier P. Double blind controlled trial of a new colonic antispasmodic agent, actylonium bromide. Ars Medici Revue Internationale De Therapie Pratique. 1981;36:1879-80. (Pubitemid 12025698)
36. Baldi F, Longanesi A, Blasi A, et al. Clinical and functional evaluation of the efficacy of otilonium bromide: a multicenter study in Italy. Ital J Gastroenterol. 1991;23:60-3.
37. Battaglia G, Morselli-Labate AM, Camarri E, et al. Otilonium bromide in irritable bowel syndrome: a double-blind, placebo-controlled, 15-week study. Aliment Pharmacol Ther. 1998;12:1003-10. (Pubitemid 28454384)
38. Castiglione F Daniele B, Mazzacca G. Therapeutic strategy for the irritable bowel syndrome. Ital J Gastroenterol. 1991;23:53-5.
39. Glende M, Morselli-Labate AM. Extended analysis of a double-blind, placebo-controlled, 15-week study with otilonium bromide in irritable bowel syndrome. Eur J Gastroenterol Hepatol. 2002;14:1138-331.
40. Ritchie JA, Truelove SC. Treatment of irritable bowel syndrome with lorazepam, hyoscine butylbromide, and ispaghula husk. Br Med J. 1979;1:376-8. (Pubitemid 9095236)
41. Nigam P, Kapoor KK, Rastog CK, et al. Different therapeutic regimens in irritable bowel syndrome. J Assoc Physicians India. 1984;32:1041-4.
42. Shafer VEEK. Behandlung des colon irritabile. Fortschr Med. 1990;25:488-92.
43. Fielding JF. Double blind trial of trimebutine in the irritable bowel syndrome. Ir Med J. 1980;73:377-9. (Pubitemid 11205856)
44. Moshal MG, Herron M. A clinical trial of trimebutine (Mebutin) in spastic colon. J Int Med Res. 1979;7:231-4. (Pubitemid 9188462)
45. Luttecke K. A trial of trimebutine in spastic colon. J Int Med Res. 1978;6:86-8.
46. Luttecke K. A three-part controlled study of trimebutine in the treatment of irritable colon syndrome. Curr Med Res Opin. 1980;6:437-43. (Pubitemid 10111293)
47. Mitchell SA, Mee AS, Smith GD, et al. Alverine citrate fails to relieve the symptoms of irritable bowel syndrome: results of a double-blind, randomized, placebo-controlled trial. Aliment Pharmacol Ther. 2002;16:1187-95. (Pubitemid 34680763)
48. Wittmann T Paradowski L, Ducrotte P, et al. Clinical trial: the efficacy of alverine citrate/simeticone combination on abdominal pain/discomfort in irritable bowel syndrome - a randomized, double-blind, placebo-controlled study. Aliment Pharmacol Ther. 2010;31:615-24.
49. Page JG, Dirnberger GM. Treatment of the irritable bowel syndrome with Bentyl (dicyclomine hydrochloride). J Clin Gastroenterol. 1981;3:153-6. (Pubitemid 11113503)